HOME >> MEDICINE >> NEWS
Clinical trial participants fare no better, no worse than other patients

People who participate in randomized controlled studies to test new therapies seem to fare no better or no worse than those who receive the same care outside of such studies, a new review of research has found.1

The finding was published against a backdrop of debate about drug trials for popular pain-relievers and about whether trial results can be safely applied to an entire population. "These results challenge the assertion that the results of RCTs (randomized controlled trials) are not applicable to usual clinical practice," report the authors, who say this review is the most comprehensive of its kind conducted to date.

A randomized clinical trial is considered the "gold standard" of medical research because it is the best way to make sure that the only difference between the groups that are compared is the treatment they receive. Patients are assigned to each group randomly in order to increase the probability that differences between the groups can be attributed only to the treatment under study.

Critics, however, say the rigorous standards for inclusion in trials and the nature of those who conduct and participate in them mean that when a new drug or treatment is applied to a general population, the results might be different.

A recent article in the prestigious journal The Lancet suggested that clinical trials cannot be expected to be relevant to all patients with the same conditions for a number of reasons, such as selecting trial participants who are in better overall health, excluding people who have conditions in addition to the one being studied and the reality that in a general population patients will not always act according to doctors' instructions.

In the new study, researchers led by Gunn Elisabeth Vist of the Norwegian Health Services Research Centre, systematically identified and reviewed 55 studies involving a total of more than 31,000 patients who were treated in randomized clinical trials an
'"/>

Contact: GE Vist
gev@nhscr.no
Center for the Advancement of Health
23-Jan-2005


Page: 1 2 3

Related medicine news :

1. Clinical breast examination offers modest benefit to breast cancer screening program
2. Clinical trial of Etanercept for Wegeners disease shows no benefit
3. Clinical trial shows drug may offer a new option to prevent rejection of transplanted kidneys
4. National Academies news: Clinical research involving children
5. Clinical research key in advance to prospective health care
6. Clinical trial of new TB vaccine begins
7. Clinical trial of Alzheimers disease drug shows clear reductions in AD development
8. Clinical factors useful to identify heart failure patients with high risk of death
9. Panel: Clinical use of embryonic stem cells jeopardized by Bushs policy on federal funding
10. $7 million grant continues Asthma Clinical Research Network efforts
11. Clinical study of Penn State Hershey technology begins in South Africa

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Clinical trial participants fare better worse than other patients

(Date:4/18/2014)... 18, 2014) ― A new study in the ... in health-related Google searches reveals a recurring pattern that ... , Investigators from San Diego State University, the ... Campaigns, analyzed "healthy" Google searches (searches that included the ... originating in the U.S. from 2005 to 2012. They ...
(Date:4/17/2014)... identified the first genetic variant specifically associated with ... for around 10-15 per cent of all breast ... the breast cancer sub-type, called invasive lobular carcinoma, ... of this particular kind of breast cancer, which ... published today (Thursday) in the journal PloS ...
(Date:4/17/2014)... the University of California, San Diego School of Medicine ... have suffered a recent major loss are more likely ... , The study is published in this month,s issue ... , Because compassionate behaviors are associated with better health ... insights into ways to improve the outcomes of individuals ...
(Date:4/17/2014)... New Rochelle, NY, April 17, 2014U.S. military personnel ... "blast plus impact" concussive traumatic brain injury (TBI) ... were evacuated for other medical reasons. Differences in ... and depression 6-12 months after injury are reported ... , a peer-reviewed journal from Mary Ann Liebert, ...
(Date:4/17/2014)... 17, 2014 By discovering a new mechanism that ... stroke, researchers at UC Irvine and the Salk Institute ... limit or prevent stroke-induced brain damage. , A complex ... of death and primary reason for disability in the ... stroke and lets blood-borne material into the brain, causing ...
Breaking Medicine News(10 mins):Health News:New research shows people are thinking about their health early in the week 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 3Health News:The ilk of human kindness 2Health News:Long-term effects of battle-related 'blast plus impact' concussive TBI in US military 2Health News:Study IDs new cause of brain bleeding immediately after stroke 2
(Date:1/15/2014)... , January 15, 2014 Shire plc (LSE: ... the Office of Fair Trading (OFT) approval condition to the announced ... (NASDAQ: VPHM).   As a result of the waiver, ... expects to complete the tender offer on January 24, 2014 following ...
(Date:1/15/2014)... LOUISVILLE, Ky. , Jan. 15, 2014  Manufacturers, ... technologies must be able to protect their most ... (Logo: http://photos.prnewswire.com/prnh/20130716/CL46586LOGO ) Because ... Industry, it steadfastly remains one of the most ...
(Date:1/15/2014)... , Jan. 15, 2014 MultiCell Technologies, Inc. ... a U.S. provisional patent application concerning composition of matter, ... achieve targeted tumor cell death.  This ... noncoding double stranded RNA molecules (VSRNAs) which interfere with ...
Breaking Medicine Technology:Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3Intellectual Property Insurance for Medical-related Products and Services 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3
Cached News: